A Phase 1/1b, Open-Label Multi-Center Two Part Study Of Setd2 Inhibitor Ezm0414 In Subjects With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Diffuse Large B Cell Lymphoma Read more
A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia Read more
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma Read more
Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma Read more
A Phase 3 Randomized Study Comparing Teclistamab In Combination With Daratumumab SC (Tecdara) Versus Daratumumab SC, Pomalidomide And Dexamethasone (Dpd) Or Daratumumab SC, Bortezomib, And Dexamethasone (Dvd) In Participants With Relapsed Or Refractory Multiple Myeloma Read more
Treatment Patterns And Adverse Event Management In Patients Treated With Selinexor In Combination With Other Approved Agents For Relapsed/Refractory Multiple Myeloma: Real-World Evidence Based On Electronic Medical Record Data Read more
